Use of Partial Area Under the Curve in Bioavailability or Bioequivalence Assessments: A Regulatory Perspective.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
23
11
2020
accepted:
29
12
2020
pubmed:
26
1
2021
medline:
12
10
2021
entrez:
25
1
2021
Statut:
ppublish
Résumé
Peak drug concentration (C
Substances chimiques
Abuse-Deterrent Formulations
0
Delayed-Action Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-887Informations de copyright
Published 2021. This article is a U.S. Government work and is in the public domain in the USA.
Références
FDA Draft Guidance for Industry: Bioavailability Studies Submitted in NDAs or INDs - General Considerations <https://www.fda.gov/media/121311/download> (2019). Accessed October 30, 2020.
FDA Draft Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA <https://www.fda.gov/media/87219/download> (2013). Accessed October 30, 2020.
Shargel, L., Yu, A. Applied biopharmaceutics and pharmacokinetics, 4th edn (eds. Shargel, L. & Yu, A.). (Appleton & Lange, Stamford, CT, 1999).
Dewland, P.M., Reader, S. & Berry, P. Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. BMC Clin. Pharmacol. 9, 19 (2009).
Lee, L.H., Choi, C., Gershkovich, P., Barr, A.M., Honer, W.G. & Procyshyn, R.M. Proposing the use of partial AUC as an adjunctive measure in establishing bioequivalence between deltoid and gluteal administration of long-acting injectable antipsychotics. Eur. J. Drug Metab. Pharmacokinet. 41, 659-664 (2016).
Healthy Canada Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.html> (2012). Accessed October 30, 2020.
EMA Guideline on the investigation of bioequivalence <https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf> (2010). Accessed October 30, 2020.
EMA Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms <https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf> (2015). Accessed October 30, 2020.
Wen, H. & Kinam, P. Introduction and overview of oral controlled release formulation design. In Oral controlled release formulation design and drug delivery (eds. Wen, H. & Park K.) (John Wiley & Sons Inc., Hoboken, NJ, 2010).
Zhu, H.U.R., Mehta, M. & Yu, L.X. Partial area under the curve: an additional pharmacokinetic metric for bioavailability and bioequivalence assessments. In FDA Bioequivalence Standards. (eds. Yu, L. & Li, B.) 165-190 (Springer, New York, NY, 2014).
Chen, M.L. An alternative approach for assessment of rate of absorption in bioequivalence studies. Pharm. Res. 9, 1380-1385 (1992).
FDA Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations <https://www.fda.gov/media/76764/download> (2002). Accessed February 8, 2020.
FDA Guidance on Zolpidem <https://www.accessdata.fda.gov/drugsatfda_docs/psg/Zolpidem_ERtab_21774_RC8-09.pdf> (2011). Accessed October 30, 2020.
FDA Draft Guidance on Methylphenidate Hydrochloride <https://www.accessdata.fda.gov/drugsatfda_docs/psg/Methylphenidate%20Hydrochloride_draft_Oral%20caps%20ER_RLD%2021284_RC03-15.pdf> (2015). Accessed October 30, 2020.
Fourie Zirkelbach, J., Jackson, A.J., Wang, Y. & Schuirmann, D.J. Use of partial AUC (PAUC) to evaluate bioequivalence-a case study with complex absorption: methylphenidate. Pharm. Res. 30, 191-202 (2013).
Lionberger, R.A., Raw, A.S., Kim, S.H., Zhang, X. & Yu, L.X. Use of partial AUC to demonstrate bioequivalence of Zolpidem Tartrate extended release formulations. Pharm. Res. 29, 1110-1120 (2012).
Stier, E.M. et al. Use of partial area under the curve metrics to assess bioequivalence of methylphenidate multiphasic modified release formulations. AAPS J. 14, 925-926 (2012).
FDA Draft Guidance on Naloxone Hydrochloride <https://www.accessdata.fda.gov/drugsatfda_docs/psg/Naloxone%20hydrochloride_%20nasal%20spray_%20NDA%20208411_RC04-17.pdf> (2017). Accessed October 30, 2020.
Swanson, J.M. et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113, e206-e216 (2004).
Gonzalez, M.A. et al. Methylphenidate bioavailability from two extended-release formulations. Int. J. Clin. Pharmacol. Ther. 40, 175-184 (2002).
Markowitz, J.S. et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet 42, 393-401 (2003).
Abuse-Deterrent Opioid Analgesics <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics> (2019). Accessed October 30, 2020.
FDA Draft Guidance on Hydrocodone Bitartrate <https://www.accessdata.fda.gov/drugsatfda_docs/psg/Hydrocodone%20thbitartrate_oral%20thER%20thtablet_NDA%20th20th6627_RV07-18.pdf> (2018). Accessed October 30, 2020.
FDA labeling: HYSINGLATM ER (hydrocodone bitartrate) extended-release tablets, for oral use, CII <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/206627s010lbl.pdf> (2019). Accessed October 30, 2020.
FDA Guidance for Industry: General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry <https://www.fda.gov/media/96643/download> (2017). Accessed October 30, 2020.
Zhao, L. Quantitative Analysis of Opioid ADF PK/PD. In ASCPT 2019 Annual Meeting. <https://www.ascpt.org/Portals/28/docs/Annual%20Meetings/2019%20Annual%20Meeting/Speaker%20Presentations/Friday/03152019%20SaS%20Evaluating%20Abuse%20L%20Zhao.pdf?ver=2019-04-03-072701-110>. Accessed February 2, 2021.
FDA labeling: SUBLOCADE (buprenorphine extended-release) injection, for subcutaneous use CIII <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209819s012lbl.pdf> (2020). Accessed October 30, 2020.
SUBLOCADE clinical pharmacology and biopharmaceutics review(s) Drugs@FDA <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209819Orig1s000ClinPharmR.pdf> (2017). Accessed October 30, 2020.
FDA Draft Guidance on Buprenorphine <https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_209819.pdf> (2020). Accessed October 30, 2020.
FDA labeling: APRISO® (mesalamine) extended-release capsules <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022301s014lbl.pdf> (2019). Accessed October 30, 2020.
Yu, A. et al. Measurement of in vivo gastrointestinal release and dissolution of three locally acting mesalamine formulations in regions of the human gastrointestinal tract. Mol. Pharm. 14, 345-358 (2017).
De Vos, M. Clinical pharmacokinetics of slow release mesalazine. Clin. Pharmacokinet. 39, 85-97 (2000).
Citizen Petition Salix Pharmaceuticals Inc FDA-2013-P-0470-0001 <https://www.regulations.gov/document?D=FDA-2013-P-0470-0001> (2013). Accessed October 30, 2020.
Myers, B. et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 28, 196-200 (1987).
FDA/CDER to Salix Pharmaceuticals, Inc. - Letter <https://www.regulations.gov/document?D=FDA-2013-P-0470-0003> (2013). Accessed October 30, 2020.
FDA Draft Guidance on Mesalamine <https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022301.pdf> (2019). Accessed October 30, 2020.
FDA Draft Guidance on Scopolamine <https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_017874.pdf> (2019). Accessed October 30, 2020.
FDA Product-Specific Guidances for Generic Drug Development <https://www.accessdata.fda.gov/scripts/cder/psg/index.cfm> (2020). Accessed October 30, 2020.
Chen, M.L., Davit, B., Lionberger, R., Wahba, Z., Ahn, H.Y. & Yu, L.X. Using partial area for evaluation of bioavailability and bioequivalence. Pharm. Res. 28, 1939-1947 (2011).